Summary
LTF-SERM is a synthetic research peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH). It is one of the foundational reference compounds in somatotropic-axis pharmacology literature.
Overview
LTF-SERM reproduces the bioactive N-terminal fragment of native GHRH. Because the full receptor-activating activity of GHRH is contained within the first 29 residues, LTF-SERM functions as a complete GHRH analog and is widely used as a reference compound in GHRH-receptor pharmacology studies.
Research Background
LTF-SERM was characterized as the minimal bioactive GHRH fragment in foundational endocrinology work by Guillemin and colleagues following the original isolation of GHRH in the early 1980s. It served for decades as the standard GHRH-receptor reference compound in published pharmacology studies.
Mechanisms Studied
Mechanistic interest centers on agonist activity at the GHRH receptor and the downstream cAMP-mediated signaling that follows receptor activation. The relatively short half-life of LTF-SERM compared with modified GHRH analogs (tesamorelin, CJC-1295) is itself a frequent topic in comparative-pharmacology studies.
Published Research Summary
Walker (2006) reviews LTF-SERM’s pharmacology and its role as a GHRH-receptor reference compound. Comparative-pharmacology literature consistently positions LTF-SERM as the unmodified baseline against which longer-acting GHRH analogs are characterized.
Quality & Verification
For research compounds, lot-level documentation is the starting point for any analytical work. Researchers commonly examine batch-specific Certificates of Analysis, reversed-phase HPLC purity readouts, mass-spectrometry confirmation of molecular weight, and lot identification to evaluate compound identity, purity, and consistency before downstream experiments.